Compare McKesson Corporation (MCK) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Petróleo Brasileiro SA — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Petróleo Brasileiro SA trades at $18.29 (market cap $108.78B). The key difference: McKesson Corporation and Petróleo Brasileiro SA are close in size by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.81%). Which is the better fit depends on your goals.
| MCK | PBR | |
|---|---|---|
Market Cap | $97.35B | $108.78B |
Sector | Health | Technology |
52-Week High | $995.69 | $22.03 |
52-Week Low | $659.01 | $11.54 |
Enterprise Value | $101.98B | $171.32B |
Dividend Yield | 0.39% | 9.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Petrobras (PBR) trades at $18.19, up 1.22% with bullish technical indicators and strong fundamentals. The stock shows robust profitability with 21.47% net margins and attractive valuation at 5.73 P/E. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. The company maintains strong cash flow generation of $197.5B operating cash flow in 2025 and recently announced strategic acquisitions and renewable energy investments.
PBR presents compelling value with deep discount valuation and 50% analyst buy ratings. Key opportunities include production growth initiatives and dividend sustainability, while risks involve commodity price volatility and geopolitical factors in Latin American operations. The stock's current technical strength combined with fundamental undervaluation supports a positive medium-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
